Last reviewed · How we verify
RHB-102
RHB-102 is a gastric motility agent.
RHB-102 is a gastric motility agent. Used for Nausea and vomiting associated with chemotherapy.
At a glance
| Generic name | RHB-102 |
|---|---|
| Sponsor | RedHill Biopharma Limited |
| Drug class | Gastric motility agent |
| Target | Ghrelin receptor |
| Modality | Small molecule |
| Therapeutic area | Gastrointestinal |
| Phase | Phase 3 |
Mechanism of action
It works by inhibiting the action of ghrelin, a hormone that stimulates appetite and gastric contractions, thereby reducing nausea and vomiting.
Approved indications
- Nausea and vomiting associated with chemotherapy
Common side effects
- Nausea
- Vomiting
- Diarrhea
Key clinical trials
- BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis (PHASE3)
- Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RHB-102 CI brief — competitive landscape report
- RHB-102 updates RSS · CI watch RSS
- RedHill Biopharma Limited portfolio CI